News
MRKR
3.980
+1.27%
0.050
Weekly Report: what happened at MRKR last week (0520-0524)?
Weekly Report · 3d ago
Weekly Report: what happened at MRKR last week (0513-0517)?
Weekly Report · 05/20 11:02
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024
Investorplace · 05/16 03:53
Marker Therapeutics, Inc. Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024
Press release · 05/16 03:52
Marker Therapeutics’ Promising Cancer Therapy Progress
TipRanks · 05/16 01:51
Marker Therapeutics GAAP EPS of -$0.27 misses by $0.02, revenue of $1.24M
Seeking Alpha · 05/15 21:07
*Marker Therapeutics Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses Into 4Q 2025 >MRKR
Dow Jones · 05/15 20:22
MARKER THERAPEUTICS INC: BELIEVES THAT EXISTING CASH AND CASH EQUIVALENTS WILL FUND ITS OPERATING EXPENSES INTO Q4 OF 2025
Reuters · 05/15 20:15
MARKER THERAPEUTICS Q1 NET INCOME USD -2.4 MILLION
Reuters · 05/15 20:15
Weekly Report: what happened at MRKR last week (0506-0510)?
Weekly Report · 05/13 11:11
Weekly Report: what happened at MRKR last week (0429-0503)?
Weekly Report · 05/06 11:18
Marker Therapeutics Initiated at Buy by Ladenburg Thalmann
Dow Jones · 04/30 14:13
Marker Therapeutics Price Target Announced at $11.00/Share by Ladenburg Thalmann
Dow Jones · 04/30 14:13
Ladenburg Thalmann Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $11
Benzinga · 04/30 14:03
Weekly Report: what happened at MRKR last week (0422-0426)?
Weekly Report · 04/29 11:25
Weekly Report: what happened at MRKR last week (0415-0419)?
Weekly Report · 04/22 11:13
Weekly Report: what happened at MRKR last week (0408-0412)?
Weekly Report · 04/15 11:05
Marker Therapeutics’ MT-601 Shows Promising Results
TipRanks · 04/08 16:07
Weekly Report: what happened at MRKR last week (0401-0405)?
Weekly Report · 04/08 11:10
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Barchart · 04/08 06:00
More
Webull provides a variety of real-time MRKR stock news. You can receive the latest news about Marker Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.